10-K: Aquestive Therapeutics Reports Mixed 2024 Results Amidst Libervant Legal Challenge

Sentiment:

Annual Results 5 March 2025 4:29 PM

📋All filings for Aquestive Therapeutics, INC

Aquestive Therapeutics' 2024 results highlight progress in proprietary pipeline development alongside challenges in commercial execution and a significant legal hurdle for its newly launched Libervant.

Capital raiseThe company may need to raise substantial funds in the future to fund its operations.The company is exploring various options for additional capital, including its ATM facility and potential asset sales or outlicensing opportunities.

Worse than expectedThe company's net loss increased significantly from $7.9 million in 2023 to $44.1 million in 2024.Manufacture and supply revenue decreased by 9% due to lower Suboxone revenues.The company is facing a legal challenge that could block Libervant from remaining in the U.S. market.

Summary

Aquestive Therapeutics reported its 10-K filing for the fiscal year ended December 31, 2024.
The company is focused on advancing medicines through innovative science and delivery technologies.
Aquestive's proprietary product, Libervant, launched in April 2024, faces a legal challenge regarding its U.S. market access.
The company is also progressing its Anaphylm and Adrenaverse epinephrine prodrug pipeline.
Licensed commercialized products continue to be manufactured and marketed by licensees.
Total revenue increased by 14% to $57.6 million in 2024, driven by license and royalty revenue and co-development fees, but offset by a decrease in manufacture and supply revenue.
The company incurred a net loss of $44.1 million, compared to a net loss of $7.9 million in the previous year.
As of December 31, 2024, Aquestive had $71.5 million in cash and cash equivalents.
The company is pursuing additional capital through its ATM facility and may consider asset sales or outlicensing opportunities.
Aquestive is appealing the court's decision regarding Libervant and is continuing to market the product pending a final ruling.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in the pipeline and revenue growth, the significant net loss and legal challenges surrounding Libervant temper the overall outlook.

Positives

Total revenue increased by 14% to $57.6 million in 2024.
The company launched Libervant in April 2024 for pediatric epilepsy patients aged two to five.
Aquestive received positive pre-NDA feedback from the FDA regarding Anaphylm.
The company is progressing with the development of AQST-108 for alopecia areata, with plans to initiate a Phase 2a clinical trial in the second quarter of 2025.
The company has a strong patent portfolio with at least 110 issued patents worldwide.

Negatives

Aquestive is facing a legal challenge from Neurelis regarding Libervant's market exclusivity, which could force the company to withdraw the product from the U.S. market.
The company incurred a net loss of $44.1 million in 2024, significantly higher than the $7.9 million loss in 2023.
Manufacture and supply revenue decreased by 9% due to lower Suboxone revenues.
The company has a significant level of debt and debt service obligations.
The company is dependent on the commercial success of its licensed and proprietary products to generate revenue.

Risks

The legal challenge from Neurelis could block Libervant from remaining in the U.S. market.
The company may need to raise substantial funds in the future to fund its operations, and these funds may not be available on acceptable terms.
The development of pharmaceutical products involves a lengthy and expensive process with an uncertain outcome.
The company faces significant competition from other pharmaceutical companies.
The company's ability to commercialize its product candidates will depend on the extent to which reimbursement will be available from government and health administration authorities.
Cybersecurity incidents could disrupt the company's operations.

Future Outlook

Aquestive plans to continue developing Anaphylm and AQST-108, commercializing Libervant, and managing expenses to extend its capital runway. The company anticipates launching Anaphylm in the first quarter of 2026, pending FDA approval.

Management Comments

Management expects to continue to manage business costs to prepare for a potential future decline in Suboxone revenue and other external factors affecting our business.
Management plans to continue to focus on the core drivers of value for our stockholders, including, more importantly, continued investments in our ongoing product development activities in support of Anaphylm and AQST-108.

Industry Context

The announcement reflects the challenges and opportunities in the pharmaceutical industry, including the high costs of drug development, regulatory hurdles, and the competitive landscape. The legal challenge to Libervant highlights the complexities of orphan drug exclusivity and market access.

Comparison to Industry Standards

The company competes with established pharmaceutical companies like Teva, Viatris, Amneal Pharmaceuticals, and Kaleo in the anaphylaxis market.
Aquestive's Anaphylm aims to compete with existing epinephrine auto-injectors like EpiPen and Auvi-Q, as well as the recently approved nasal spray Neffy.
In the epilepsy market, Aquestive's Libervant competes with diazepam rectal gel and the nasal spray Valtoco from Neurelis.
The company's reliance on third-party CROs and manufacturers is a common practice in the pharmaceutical industry, but it also introduces risks related to compliance and supply chain management.

Legal Proceedings

Aquestive is facing a lawsuit from Neurelis regarding Libervant's market exclusivity.
The company is involved in product liability litigation related to Suboxone.

Stakeholder Impact

Shareholders face the risk of dilution from potential future equity offerings.
Employees may be affected by potential expense management activities, such as staff reductions.
Patients could benefit from the development of new and improved treatments, but access to Libervant is currently uncertain due to the legal challenge.
Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

Aquestive plans to continue developing Anaphylm and AQST-108.
The company will continue to commercialize Libervant for pediatric patients aged two to five.
Aquestive will pursue an appeal of the court's decision regarding Libervant and seek a determination of clinical superiority from the FDA.
The company will explore various options for additional capital, including its ATM facility and potential asset sales or outlicensing opportunities.

Key Dates

Date	Description
August 15, 2008	Date of the Commercial Exploitation Agreement with Reckitt Benckiser Pharmaceuticals Inc. (later Indivior).
March 20, 2012	Date of the agreement with Zevra to terminate the Collaboration and License Agreement.
April 1, 2016	Date of the License Agreement with Cynapsus Therapeutics Inc. (later Sunovion).
September 24, 2017	Date of the Supplemental Agreement with Indivior.
July 24, 2018	Common stock began trading on the Nasdaq Global Select Market.
July 15, 2019	Date of the Indenture among Aquestive Therapeutics, Inc., as Issuer, any Guarantor that becomes party thereto and U.S. Bank National Association, as Trustee and Collateral Agent.
January 10, 2020	Competitor obtained FDA approval of its diazepam nasal spray drug candidate, Valtoco, and was granted orphan-drug-exclusivity.
May 21, 2020	KYNMOBI was approved by the FDA.
November 3, 2020	Date of the Monetization Agreement with Marathon.
March 2, 2021	Zevra announced FDA approval of Azstarys for the treatment of ADHD.
January 2021	Aquestive granted an exclusive license to MTPA for the commercialization of Exservan in the United States.
October 7, 2021	Date of the Fourth Supplemental Indenture.
April 12, 2022	Date of the Purchase Agreement with Lincoln Park.
May 17, 2022	Date of the Separation Agreement with Keith J. Kendall.
June 6, 2022	Date of the Securities Purchase Agreements with certain purchasers.
August 2022	FDA granted tentative approval for Libervant for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity in patients with epilepsy 12 years of age and older.
September 26, 2022	Date of the Pharmanovia Agreement.
October 26, 2022	Date of the License Agreement with Otter Pharmaceuticals, LLC (Assertio).
March 27, 2023	Date of the amendment to the Pharmanovia Agreement to expand the scope of the licensed territory for Libervant.
November 1, 2023	Aquestive issued $45 million aggregate principal amount of 13.5% Notes.
April 26, 2024	FDA approved Libervant for U.S. market access for ARS patients between two and five years of age.
February 14, 2025	U.S. District Court for the District of Columbia issued a final appealable order vacating the FDAs approval of Libervant for ARS patients aged between two and five years.
February 24, 2025	Aquestive filed a request with the FDA that the FDA also confirms approval of Libervant for ARS patients aged between two and five years on the FDA regulatory grounds of clinical superiority.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.